Last reviewed · How we verify
T3 Suppression for Thyroid Function Test — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Triostat | LIOTHYRONINE | Pfizer | l-Triiodothyronine | Thyroid hormone receptor alpha | 1956-01-01 | |
| Triiodothyronine | Triiodothyronine | Northwell Health | THAP domain-containing protein 1, Cytochrome P450 2C9, Proliferating cell nuclear antigen |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Northwell Health · 1 drug in T3 Suppression for Thyroid Function Test
- Pfizer · 1 drug in T3 Suppression for Thyroid Function Test
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in T3 Suppression for Thyroid Function Test:
- T3 Suppression for Thyroid Function Test treatment updates — RSS
- T3 Suppression for Thyroid Function Test treatment updates — Atom
- T3 Suppression for Thyroid Function Test treatment updates — JSON
Cite this brief
Drug Landscape (2026). T3 Suppression for Thyroid Function Test — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/t3-suppression-for-thyroid-function-test. Accessed 2026-06-10.
Related
- T3 Suppression for Thyroid Function Test full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing